← 返回

接受术前化疗的乳腺癌患者体重指数与肿瘤免疫应答的临床验证

英文原题:Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy.

查看英文原题

Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy.

PubMed 2021/10/20(内容时间) BMC Cancer Q2 · IF 4.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们的数据未支持肥胖影响肿瘤免疫微环境的假设;然而我们发现,处于 UW 状态确实会影响肿瘤免疫微环境。

中文摘要

体重指数(BMI)常被用作简便的肥胖指标;研究显示,按BMI判定为肥胖(OB)的早期乳腺癌患者术后复发率较高、生存率较低。另一方面,参与肿瘤免疫应答、存在于恶性肿瘤附近的淋巴细胞会影响化疗疗效。因此我们假设,肥胖乳腺癌患者的TIL(肿瘤浸润淋巴细胞)密度较低,进而可能影响术前化疗(POC)效果。本研究测量接受POC的乳腺癌患者治疗前BMI和TIL,考察二者相关性,并回顾性分析其治疗结局和预后。

研究对象为2007年2月至2019年1月接受POC后手术的421例乳腺癌患者。治疗前测量身高和体重并计算BMI〔体重(kg)除以身高(m)的平方〕。按世界卫生组织分类,BMI低于18.5 kg/m²为体重过轻(UW);18.5 kg/m²至25 kg/m²以下为正常体重(NW);25 kg/m²至30 kg/m²以下为超重(OW);30 kg/m²及以上为肥胖(OB)。根据国际TIL工作组2014年的定义,将浸润肿瘤间质的淋巴细胞计为TIL。

BMI中位数为21.9 kg/m²(范围14.3–38.5 kg/m²);大多数患者(244例;64.5%)为NW。在全部378例乳腺癌患者中,OB患者的TIL密度显著低于NW和OW患者(分别比较:与NW相比p=0.001;与OW相比p=0.003)。此外,对各乳腺癌亚型分别分析时,低BMI三阴性乳腺癌(TNBC)患者的OS显著差于高BMI患者(log-rank p=0.031)。

我们的数据不支持肥胖影响肿瘤免疫微环境这一假设;但显示体重过轻确实会影响肿瘤免疫微环境。

展开英文摘要原文

The body mass index (BMI) is commonly used as a simple indicator of obesity; patients with early-stage breast cancer who are obese (OB) per BMI measurements have been shown to have high postoperative recurrence and low survival rates. On the other hand, it has been shown that lymphocytes present in the vicinity of malignant growths that are involved in the tumors' immune responses influence the efficacy chemotherapy. Therefore, we hypothesized that OB patients with breast cancer have a lower density of tumor-infiltrating lymphocytes (TILs), which may influence the therapeutic effect of preoperative chemotherapy (POC). In this study, we measured pretreatment BMI and TILs in patients with breast cancer who underwent POC, examined the correlations between these two factors, and retrospectively analyzed their therapeutic outcomes and prognoses.

The participants in this study were 421 patients with breast cancer who underwent surgical treatment after POC between February 2007 and January 2019. The patient's height and weight were measured before POC to calculate the BMI (weight [kg] divided by the square of the height [m 2 ]). According to the World Health Organization categorization, patients who weighed under 18.5 kg/m 2 were classified as underweight (UW), those 18.5 kg/m 2 and > 25 kg/m 2 were considered normal weight (NW), those 25 kg/m 2 and < 30 kg/m 2 were overweight (OW), and those 30 kg/m 2 were OB. The TILs were those lymphocytes that infiltrated the tumor stroma according to the definition of the International TILs Working Group 2014.

The median BMI was 21.9 kg/m 2 (range, 14.3-38.5 kg/m 2 ); most patients (244; 64.5%) were NW. Among all 378 patients with breast cancer, the TIL density was significantly lower in OB than in NW and OW patients (vs. NW: p = 0.001; vs. OW: p = 0.003). Furthermore, when examining patients with each breast cancer type individually, the OS of those with TNBC who had low BMIs was significantly poorer than that of their high-BMI counterparts (log rank p = 0.031).

Our data did not support the hypothesis that obesity affects the tumor immune microenvironment; however, we showed that being UW does affect the tumor immune microenvironment.

论文信息

作者
Takada K、Kashiwagi S、Asano Y、Goto W、Ishihara S、Morisaki T、Shibutani M、Tanaka H
第一作者单位
Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan.Japan
通讯作者单位
Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan. spqv9ke9@view.ocn.ne.jp.Japan
期刊
BMC cancer2021 Oct 20
原文标识
PubMed 34670511 · DOI 10.1186/s12885-021-08857-7